Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease

Sandro Rossetti, Mark B. Consugar, Arlene B. Chapman, Vicente Torres, Lisa M. Guay-Woodford, Jared J. Grantham, William M. Bennett, Catherine M. Meyers, Denise L. Walker, Kyongtae Bae, Qin Zhang, Paul A. Thompson, J. Philip Miller, Peter C Harris

Research output: Contribution to journalArticle

259 Citations (Scopus)

Abstract

Mutation-based molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) is complicated by genetic and allelic heterogeneity, large multi-exon genes, duplication of PKD1, and a high level of unclassified variants (UCV). Present mutation detection levels are 60 to 70%, and PKD1 and PKD2 UCV have not been systematically classified. This study analyzed the uniquely characterized Consortium for Radiologic Imaging Study of PKD (CRISP) ADPKD population by molecular analysis. A cohort of 202 probands was screened by denaturing HPLC, followed by direct sequencing using a clinical test of 121 with no definite mutation (plus controls). A subset was also screened for larger deletions, and reverse transcription-PCR was used to test abnormal splicing. Definite mutations were identified in 127 (62.9%) probands, and all UCV were assessed for their potential pathogenicity. The Grantham Matrix Score was used to score the significance of the substitution and the conservation of the residue in orthologs and defined domains. The likelihood for aberrant splicing and contextual information about the UCV within the patient (including segregation analysis) was used in combination to define a variant score. From this analysis, 44 missense plus two atypical splicing and seven small in-frame changes were defined as probably pathogenic and assigned to a mutation group. Mutations were thus defined in 180 (89.1%) probands: 153 (85.0%) PKD1 and 27 (15.0%) PKD2. The majority were unique to a single family, but recurrent mutations accounted for 30.0% of the total. A total of 190 polymorphic variants were identified in PKD1 (average of 10.1 per patient) and eight in PKD2. Although nondefinite mutation data must be treated with care in the clinical setting, this study shows the potential for molecular diagnostics in ADPKD that is likely to become increasingly important as therapies become available.

Original languageEnglish (US)
Pages (from-to)2143-2160
Number of pages18
JournalJournal of the American Society of Nephrology
Volume18
Issue number7
DOIs
StatePublished - Jul 2007

Fingerprint

Autosomal Dominant Polycystic Kidney
Molecular Pathology
Mutation
Gene Duplication
Genetic Heterogeneity
Reverse Transcription
Virulence
Exons
High Pressure Liquid Chromatography
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Nephrology

Cite this

Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. / Rossetti, Sandro; Consugar, Mark B.; Chapman, Arlene B.; Torres, Vicente; Guay-Woodford, Lisa M.; Grantham, Jared J.; Bennett, William M.; Meyers, Catherine M.; Walker, Denise L.; Bae, Kyongtae; Zhang, Qin; Thompson, Paul A.; Miller, J. Philip; Harris, Peter C.

In: Journal of the American Society of Nephrology, Vol. 18, No. 7, 07.2007, p. 2143-2160.

Research output: Contribution to journalArticle

Rossetti, S, Consugar, MB, Chapman, AB, Torres, V, Guay-Woodford, LM, Grantham, JJ, Bennett, WM, Meyers, CM, Walker, DL, Bae, K, Zhang, Q, Thompson, PA, Miller, JP & Harris, PC 2007, 'Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease', Journal of the American Society of Nephrology, vol. 18, no. 7, pp. 2143-2160. https://doi.org/10.1681/ASN.2006121387
Rossetti, Sandro ; Consugar, Mark B. ; Chapman, Arlene B. ; Torres, Vicente ; Guay-Woodford, Lisa M. ; Grantham, Jared J. ; Bennett, William M. ; Meyers, Catherine M. ; Walker, Denise L. ; Bae, Kyongtae ; Zhang, Qin ; Thompson, Paul A. ; Miller, J. Philip ; Harris, Peter C. / Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. In: Journal of the American Society of Nephrology. 2007 ; Vol. 18, No. 7. pp. 2143-2160.
@article{7c06facb4f9544a0b034f4648114c3da,
title = "Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease",
abstract = "Mutation-based molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) is complicated by genetic and allelic heterogeneity, large multi-exon genes, duplication of PKD1, and a high level of unclassified variants (UCV). Present mutation detection levels are 60 to 70{\%}, and PKD1 and PKD2 UCV have not been systematically classified. This study analyzed the uniquely characterized Consortium for Radiologic Imaging Study of PKD (CRISP) ADPKD population by molecular analysis. A cohort of 202 probands was screened by denaturing HPLC, followed by direct sequencing using a clinical test of 121 with no definite mutation (plus controls). A subset was also screened for larger deletions, and reverse transcription-PCR was used to test abnormal splicing. Definite mutations were identified in 127 (62.9{\%}) probands, and all UCV were assessed for their potential pathogenicity. The Grantham Matrix Score was used to score the significance of the substitution and the conservation of the residue in orthologs and defined domains. The likelihood for aberrant splicing and contextual information about the UCV within the patient (including segregation analysis) was used in combination to define a variant score. From this analysis, 44 missense plus two atypical splicing and seven small in-frame changes were defined as probably pathogenic and assigned to a mutation group. Mutations were thus defined in 180 (89.1{\%}) probands: 153 (85.0{\%}) PKD1 and 27 (15.0{\%}) PKD2. The majority were unique to a single family, but recurrent mutations accounted for 30.0{\%} of the total. A total of 190 polymorphic variants were identified in PKD1 (average of 10.1 per patient) and eight in PKD2. Although nondefinite mutation data must be treated with care in the clinical setting, this study shows the potential for molecular diagnostics in ADPKD that is likely to become increasingly important as therapies become available.",
author = "Sandro Rossetti and Consugar, {Mark B.} and Chapman, {Arlene B.} and Vicente Torres and Guay-Woodford, {Lisa M.} and Grantham, {Jared J.} and Bennett, {William M.} and Meyers, {Catherine M.} and Walker, {Denise L.} and Kyongtae Bae and Qin Zhang and Thompson, {Paul A.} and Miller, {J. Philip} and Harris, {Peter C}",
year = "2007",
month = "7",
doi = "10.1681/ASN.2006121387",
language = "English (US)",
volume = "18",
pages = "2143--2160",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease

AU - Rossetti, Sandro

AU - Consugar, Mark B.

AU - Chapman, Arlene B.

AU - Torres, Vicente

AU - Guay-Woodford, Lisa M.

AU - Grantham, Jared J.

AU - Bennett, William M.

AU - Meyers, Catherine M.

AU - Walker, Denise L.

AU - Bae, Kyongtae

AU - Zhang, Qin

AU - Thompson, Paul A.

AU - Miller, J. Philip

AU - Harris, Peter C

PY - 2007/7

Y1 - 2007/7

N2 - Mutation-based molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) is complicated by genetic and allelic heterogeneity, large multi-exon genes, duplication of PKD1, and a high level of unclassified variants (UCV). Present mutation detection levels are 60 to 70%, and PKD1 and PKD2 UCV have not been systematically classified. This study analyzed the uniquely characterized Consortium for Radiologic Imaging Study of PKD (CRISP) ADPKD population by molecular analysis. A cohort of 202 probands was screened by denaturing HPLC, followed by direct sequencing using a clinical test of 121 with no definite mutation (plus controls). A subset was also screened for larger deletions, and reverse transcription-PCR was used to test abnormal splicing. Definite mutations were identified in 127 (62.9%) probands, and all UCV were assessed for their potential pathogenicity. The Grantham Matrix Score was used to score the significance of the substitution and the conservation of the residue in orthologs and defined domains. The likelihood for aberrant splicing and contextual information about the UCV within the patient (including segregation analysis) was used in combination to define a variant score. From this analysis, 44 missense plus two atypical splicing and seven small in-frame changes were defined as probably pathogenic and assigned to a mutation group. Mutations were thus defined in 180 (89.1%) probands: 153 (85.0%) PKD1 and 27 (15.0%) PKD2. The majority were unique to a single family, but recurrent mutations accounted for 30.0% of the total. A total of 190 polymorphic variants were identified in PKD1 (average of 10.1 per patient) and eight in PKD2. Although nondefinite mutation data must be treated with care in the clinical setting, this study shows the potential for molecular diagnostics in ADPKD that is likely to become increasingly important as therapies become available.

AB - Mutation-based molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) is complicated by genetic and allelic heterogeneity, large multi-exon genes, duplication of PKD1, and a high level of unclassified variants (UCV). Present mutation detection levels are 60 to 70%, and PKD1 and PKD2 UCV have not been systematically classified. This study analyzed the uniquely characterized Consortium for Radiologic Imaging Study of PKD (CRISP) ADPKD population by molecular analysis. A cohort of 202 probands was screened by denaturing HPLC, followed by direct sequencing using a clinical test of 121 with no definite mutation (plus controls). A subset was also screened for larger deletions, and reverse transcription-PCR was used to test abnormal splicing. Definite mutations were identified in 127 (62.9%) probands, and all UCV were assessed for their potential pathogenicity. The Grantham Matrix Score was used to score the significance of the substitution and the conservation of the residue in orthologs and defined domains. The likelihood for aberrant splicing and contextual information about the UCV within the patient (including segregation analysis) was used in combination to define a variant score. From this analysis, 44 missense plus two atypical splicing and seven small in-frame changes were defined as probably pathogenic and assigned to a mutation group. Mutations were thus defined in 180 (89.1%) probands: 153 (85.0%) PKD1 and 27 (15.0%) PKD2. The majority were unique to a single family, but recurrent mutations accounted for 30.0% of the total. A total of 190 polymorphic variants were identified in PKD1 (average of 10.1 per patient) and eight in PKD2. Although nondefinite mutation data must be treated with care in the clinical setting, this study shows the potential for molecular diagnostics in ADPKD that is likely to become increasingly important as therapies become available.

UR - http://www.scopus.com/inward/record.url?scp=34447286491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447286491&partnerID=8YFLogxK

U2 - 10.1681/ASN.2006121387

DO - 10.1681/ASN.2006121387

M3 - Article

VL - 18

SP - 2143

EP - 2160

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 7

ER -